Emergent Biosolutions Financials
0IGA Stock | 10.00 0.18 1.83% |
Operating Margin 0.2451 | PE Ratio 0.0337 | Profit Margin (0.19) | Return On Equity (0.35) |
Emergent | Select Account or Indicator |
Understanding current and past Emergent Biosolutions Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Emergent Biosolutions' financial statements are interrelated, with each one affecting the others. For example, an increase in Emergent Biosolutions' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Check Emergent Biosolutions' Beneish M Score to see the likelihood of Emergent Biosolutions' management manipulating its earnings.
Emergent Biosolutions Stock Summary
Emergent Biosolutions competes with MTI Wireless, Hochschild Mining, Air Products, Games Workshop, and Litigation Capital. Emergent Biosolutions is entity of United Kingdom. It is traded as Stock on LSE exchange.Foreign Associate | Germany |
Specialization | Industrials, Commercial & Professional Services |
Instrument | UK Stock View All |
Exchange | London Exchange |
Business Address | 400 Professional Drive, |
Sector | Commercial Services & Supplies |
Industry | Industrials |
Benchmark | Dow Jones Industrial |
Website | www.emergentbiosolutions.com |
Phone | 240 631 3200 |
You should never invest in Emergent Biosolutions without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Emergent Stock, because this is throwing your money away. Analyzing the key information contained in Emergent Biosolutions' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Emergent Biosolutions Key Financial Ratios
There are many critical financial ratios that Emergent Biosolutions' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Emergent Biosolutions reports annually and quarterly.Revenue | 1.05 B | ||||
Gross Profit | 290.1 M | ||||
EBITDA | (505.3 M) | ||||
Net Income | (760.5 M) | ||||
Total Asset | 1.82 B |
Emergent Biosolutions Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.3B | 2.9B | 3.0B | 3.2B | 1.8B | 1.2B | |
Net Debt | 643.5M | 253.5M | 264.9M | 763.2M | 748.5M | 785.9M | |
Cash | 167.8M | 621.3M | 576.1M | 642.6M | 111.7M | 217.0M | |
Other Assets | 27.1M | 65.6M | 1.0 | 171.9M | 197.7M | 207.6M | |
Other Current Assets | 25.2M | 73.2M | 70.4M | 57.9M | 47.9M | 27.7M | |
Total Liab | 1.2B | 1.4B | 1.3B | 1.8B | 1.2B | 1.2B | |
Long Term Debt | 13.5M | 784.5M | 798.4M | 841M | 967.2M | 590.8M | |
Capital Surpluse | 618.4M | 688.6M | 716.1M | 784.9M | 902.6M | 695.3M | |
Other Liab | 200M | 173.6M | 131M | 90.4M | 81.4M | 116.4M | |
Net Tangible Assets | 80M | 517.2M | 789.5M | 436M | 501.4M | 459.4M |
Emergent Biosolutions Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 9.9M | 38.4M | 31.3M | 34.5M | 87.9M | 92.3M | |
Total Revenue | 1.1B | 1.6B | 1.8B | 1.1B | 1.0B | 560.8M | |
Gross Profit | 672.5M | 1.0B | 1.0B | 427.2M | 343.9M | 328.4M | |
Operating Income | 114.1M | 433.8M | 352.6M | (166M) | (726.4M) | (690.1M) | |
Ebit | 116.4M | 434.6M | 331.9M | (181.8M) | (630.4M) | (598.9M) | |
Research Development | 142.8M | 226.2M | 234.5M | 234M | 111.4M | 128.2M | |
Ebitda | 227.3M | 549M | 458.2M | (32.9M) | (505.3M) | (480.0M) | |
Cost Of Revenue | 433.5M | 524M | 757.5M | 693.7M | 705.4M | 740.7M | |
Income Before Tax | 77.4M | 407.2M | 314.4M | (221.7M) | (731.2M) | (694.6M) | |
Net Income | 54.5M | 305.8M | 219.5M | (223.8M) | (760.5M) | (722.5M) | |
Income Tax Expense | 18.8M | 22.9M | 102.1M | 83.5M | 29.3M | 24.3M | |
Tax Provision | 35.8M | 23.1M | 22.9M | 102.1M | 117.4M | 123.3M | |
Interest Income | 4.8M | 9.9M | 38.4M | 31.3M | 36.0M | 20.0M |
Emergent Biosolutions Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (1.9M) | (16.7M) | (83.2M) | (51.9M) | 600K | 630K | |
Change In Cash | (66.9M) | 55.6M | 453.5M | 66.3M | (530.9M) | (504.4M) | |
Free Cash Flow | (30.3M) | 101.1M | 395M | (149.9M) | (257.9M) | (245.0M) | |
Depreciation | 62.2M | 110.7M | 114.5M | 143.3M | 125.1M | 131.4M | |
Other Non Cash Items | 37.6M | 59M | 33.5M | 19.8M | 485.2M | 509.5M | |
Capital Expenditures | 72.1M | 86.9M | 141M | 115.8M | 51.6M | 76.4M | |
Net Income | 62.7M | 54.5M | 305.1M | (223.8M) | (760.5M) | (722.5M) | |
End Period Cash Flow | 112.4M | 168M | 621.5M | 642.6M | 111.7M | 106.1M | |
Net Borrowings | 13.7M | 62.9M | (35.9M) | 564.2M | 648.8M | 681.3M | |
Change To Netincome | 62.2M | 104.1M | 118.7M | 41.8M | 48.1M | 71.4M |
Emergent Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Emergent Biosolutions's current stock value. Our valuation model uses many indicators to compare Emergent Biosolutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emergent Biosolutions competition to find correlations between indicators driving Emergent Biosolutions's intrinsic value. More Info.Emergent Biosolutions is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Emergent Biosolutions' earnings, one of the primary drivers of an investment's value.Emergent Biosolutions Systematic Risk
Emergent Biosolutions' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Emergent Biosolutions volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Emergent Biosolutions correlated with the market. If Beta is less than 0 Emergent Biosolutions generally moves in the opposite direction as compared to the market. If Emergent Biosolutions Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Emergent Biosolutions is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Emergent Biosolutions is generally in the same direction as the market. If Beta > 1 Emergent Biosolutions moves generally in the same direction as, but more than the movement of the benchmark.
Emergent Biosolutions Total Assets Over Time
Emergent Biosolutions November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Emergent Biosolutions help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Emergent Biosolutions. We use our internally-developed statistical techniques to arrive at the intrinsic value of Emergent Biosolutions based on widely used predictive technical indicators. In general, we focus on analyzing Emergent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Emergent Biosolutions's daily price indicators and compare them against related drivers.
Downside Deviation | 6.69 | |||
Information Ratio | 0.0288 | |||
Maximum Drawdown | 40.8 | |||
Value At Risk | (9.77) | |||
Potential Upside | 8.65 |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.